Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-25
DOI
10.1007/s40257-018-0400-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients
- (2018) Y. Mai et al. BRITISH JOURNAL OF DERMATOLOGY
- Systemic Contact Dermatitis
- (2018) Marcella Aquino et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Cutaneous manifestations of diabetes mellitus and the metabolic syndrome
- (2018) Ayse Serap Karadag et al. CLINICS IN DERMATOLOGY
- Isobornyl acrylate contained in the insulin patch pump OmniPod as the cause of severe allergic contact dermatitis
- (2018) Eva Oppel et al. CONTACT DERMATITIS
- Allergic contact dermatitis caused by isobornyl acrylate in OmniPod, an innovative tubeless insulin pump
- (2018) Nadia Raison-Peyron et al. CONTACT DERMATITIS
- Allergic contact dermatitis and diabetes medical devices: 2 clinical cases
- (2018) Stefano Passanisi et al. CONTACT DERMATITIS
- Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management
- (2018) S. Shahzad Mustafa et al. CURRENT ALLERGY AND ASTHMA REPORTS
- Economic Costs of Diabetes in the U.S. in 2017
- (2018) DIABETES CARE
- Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database
- (2018) Masanori Arai et al. DIABETES CARE
- Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital
- (2018) Guillermo E. Umpierrez et al. DIABETES CARE
- Role of omalizumab in insulin hypersensitivity: a case report and review of the literature
- (2018) S. Mishra et al. DIABETIC MEDICINE
- Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization
- (2018) Irene García-Díez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions
- (2018) Chuang-Wei Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis
- (2018) Nobuki Maki et al. JOURNAL OF DERMATOLOGY
- Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid
- (2018) Chika Chijiwa et al. JOURNAL OF DERMATOLOGY
- Don't Play with Your Nodule: Case Report of Tachycardia and Other Adverse Reactions from Manipulation of an Exenatide Injection Site Nodule
- (2018) Caitlin Sandman et al. JOURNAL OF EMERGENCY MEDICINE
- Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case control study
- (2018) O. Varpuluoma et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
- (2018) Luca Fania et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland
- (2018) Michael Benzaquen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Wound Management Strategies in Stevens-Johnson syndrome/Toxic Epidermal Necrolysis: An unmet need
- (2018) Lee Haur Yueh JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors
- (2018) A. Gravani et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area
- (2018) Hyunil Jang et al. MEDICINE
- High frequencies of dermatological complications in children using insulin pumps or sensors
- (2018) Anna Korsgaard Berg et al. PEDIATRIC DIABETES
- Association Between Pemphigus and Neurologic Diseases
- (2018) Khalaf Kridin et al. JAMA Dermatology
- Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain
- (2018) Kenta Nakama et al. JAMA Dermatology
- Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients
- (2018) Olivier Gaudin et al. Frontiers in Immunology
- Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
- (2018) Yosuke Mai et al. Frontiers in Immunology
- Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
- (2017) Masaru Harada et al. INTERNAL MEDICINE
- Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade
- (2017) L. Fania et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema
- (2017) Stephanie N. Hudey et al. Journal of Allergy and Clinical Immunology-In Practice
- Hypersensitivity reactions to human insulin analogs in insulin-naïve patients: a systematic review
- (2017) Andrew S. Bzowyckyj et al. Therapeutic Advances in Endocrinology and Metabolism
- Abnormal skin in toe webs is a marker for abnormal glucose metabolism. A cross-sectional survey among 1,849 adults in Finland
- (2017) Suvi-Päivikki Sinikumpu et al. Scientific Reports
- Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type
- (2016) P Ross et al. ACTA DIABETOLOGICA
- Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180
- (2016) A. Sakai et al. BRITISH JOURNAL OF DERMATOLOGY
- Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database
- (2016) J. Béné et al. BRITISH JOURNAL OF DERMATOLOGY
- Angioedema Phenotypes: Disease Expression and Classification
- (2016) Maddalena Alessandra Wu et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Sensitization to cyanoacrylates caused by prolonged exposure to a glucose sensor set in a diabetic child
- (2016) Jakob F. Schwensen et al. CONTACT DERMATITIS
- A case of bullous pemphigoid ınduced by vildagliptin
- (2016) Havva Ozge Keseroglu et al. Cutaneous and Ocular Toxicology
- Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin
- (2016) Francisco Manuel Ildefonso Mendonça et al. DERMATOLOGY
- Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control
- (2016) Susanne Famulla et al. DIABETES CARE
- Improvement of Insulin Injection Technique
- (2016) Geralyn Spollett et al. DIABETES EDUCATOR
- Improving Patient Experience With Insulin Infusion Sets
- (2016) Alison B. Evert et al. DIABETES EDUCATOR
- Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial
- (2016) Juan P. Frías et al. DIABETES OBESITY & METABOLISM
- Insulin Infusion Set Use: European Perspectives and Recommendations
- (2016) Dorothee Deiss et al. Diabetes Technology & Therapeutics
- Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
- (2016) M. García et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid
- (2016) Kentaro Izumi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Stevens-Johnson syndrome and toxic epidermal necrolysis: a review
- (2016) Anthony Wong et al. Revista da Associacao Medica Brasileira
- Complications of Diabetes 2016
- (2016) Konstantinos Papatheodorou et al. Journal of Diabetes Research
- Bullous Pemphigoid Associated With Linagliptin Treatment
- (2016) Roger Haber et al. JAMA Dermatology
- An Overview of Insulin Pumps and Glucose Sensors for the Generalist
- (2016) Brooke McAdams et al. Journal of Clinical Medicine
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update
- (2015) Roni P. Dodiuk-Gad et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Characteristics and Clinical Manifestations of Pigmented Purpuric Dermatosis
- (2015) Dai Hyun Kim et al. Annals of Dermatology
- Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology
- (2015) C. Feliciani et al. BRITISH JOURNAL OF DERMATOLOGY
- Acute generalized exanthematous pustulosis (AGEP): A review and update
- (2015) Jesse Szatkowski et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists
- (2015) Charles F Shaefer et al. POSTGRADUATE MEDICINE
- A Review of the Diagnosis and Management of Erythroderma (Generalized Red Skin)
- (2015) Nisha Mistry et al. Advances in Skin & Wound Care
- Abdominal lipohypertrophy without insulin injection
- (2015) Kagan Gungor et al. Lancet Diabetes & Endocrinology
- Allergic contact dermatitis caused by acrylates and methacrylates - a 7-year study
- (2014) Leonor Ramos et al. CONTACT DERMATITIS
- Erythroderma secondary to gliclazide: a case report
- (2014) Pinar Ozuguz et al. Cutaneous and Ocular Toxicology
- Acrylates in Contact Dermatitis
- (2014) Denis Sasseville Dermatitis
- DPP-4 inhibitors: focus on safety
- (2014) Sri Harsha Tella et al. Expert Opinion On Drug Safety
- Bullous pemphigoid induced by vildagliptin: a report of three cases
- (2014) Johana Béné et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Drug-induced pemphigoid: a review of the literature
- (2014) P.G. Stavropoulos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys
- (2014) Peter Hoffmann et al. TOXICOLOGIC PATHOLOGY
- Sulfonamide cross-reactivity: Is there evidence to support broad cross-allergenicity?
- (2013) N. R. Wulf et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Nateglinide in Combination with Metformin in Chinese Patients with Type 2 Diabetes Mellitus: A Post-Marketing Surveillance Study
- (2013) Jin-Kui Yang et al. CLINICAL DRUG INVESTIGATION
- Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes
- (2013) M. Blanco et al. DIABETES & METABOLISM
- Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey
- (2013) John C. Pickup et al. Diabetes Technology & Therapeutics
- A practical, clinical approach to the assessment and management of suspected insulin allergy
- (2013) J. Jacquier et al. DIABETIC MEDICINE
- Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
- (2013) Y. Saisho et al. DIABETIC MEDICINE
- The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin
- (2013) Hidetaka Hamasaki et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Acute generalized exanthematous pustulosis induced by gliclazide: a case report
- (2013) Marisol Contreras-Steyls et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Current Medical Treatment of Ocular Mucous Membrane Pemphigoid
- (2013) Bianka Sobolewska et al. Ocular Surface
- Insulin Injection Lipoatrophy Recidivus
- (2013) Arlan L Rosenbloom PEDIATRIC DIABETES
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials
- (2013) Michael Grimm et al. POSTGRADUATE MEDICINE
- A Case Report of Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
- (2013) Iman Aouidad et al. JAMA Dermatology
- The Associations Between Bullous Pemphigoid and Drug Use
- (2013) Antonia Lloyd-Lavery et al. JAMA Dermatology
- Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years
- (2012) Paul Norwood et al. CLINICAL THERAPEUTICS
- Current patch test results with the European baseline series and extensions to it from the ‘European Surveillance System on Contact Allergy’ network, 2007-2008
- (2012) Wolfgang Uter et al. CONTACT DERMATITIS
- Quantitative Model of the Relationship Between Dipeptidyl Peptidase-4 (DPP-4) Inhibition and Response: Meta-Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results
- (2012) John P. Gibbs et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lichen Planus
- (2012) Laurence Le Cleach et al. NEW ENGLAND JOURNAL OF MEDICINE
- DPP-4 inhibitors and angioedema: a cause for concern?
- (2011) Jennifer S. Byrd et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Insulin allergy
- (2011) Mohammad K. Ghazavi et al. CLINICS IN DERMATOLOGY
- Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
- (2011) Efi Pasmatzi et al. DIABETES CARE
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin
- (2011) K. Skandalis et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report
- (2011) Ernst A Chantelau et al. Diabetology & Metabolic Syndrome
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy
- (2009) Daniela Bruttomesso et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature
- (2009) Andreas Holstein et al. Expert Opinion On Drug Safety
- Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
- (2009) Nancy J. Brown et al. HYPERTENSION
- Occupational methacrylate and acrylate allergy from glues
- (2008) Kristiina Aalto-Korte et al. CONTACT DERMATITIS
- Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool-age and school-age children
- (2008) Edith Schober et al. PEDIATRIC DIABETES
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
- (2007) James Brian Byrd et al. HYPERTENSION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now